Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics (AKBA) was upgraded by Zacks Research from "strong sell" to "hold".
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates [Yahoo! Finance]